

Camrelizumab CAPTAIN-1st

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Camrelizumab CAPTAIN-1st

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Head and neck cancer  
Therapeutic Indication: First-line treatment of recurrent or metastatic nasopharyngeal carcinoma  
Experimental Arm: Camrelizumab + Gemcitabine + cisplatin  
Control Arm: Placebo + gemcitabine + cisplatin

